Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Authorization Holder Scheme To Shake Up China R&D, Drug Production

This article was originally published in SRA

Executive Summary

When a roomful of attendees at the annual ChinaTrials meeting, held Nov. 4 in Beijing, voted that a planned marketing authorization holder (MAH) system would be the single development likely to have the most impact on the pharma industry, few predicted that the scheme would come true just hours later.

Advertisement

Related Content

Dragon Tamer: New Models Needed To Capture China Opportunities
Bring On Clinical Studies: China Steps Up To Facilitate New Drug Entry
Foreign Drugs Welcome As China Reforms Progress: CFDA Commissioner
Sweeping China Policy Reforms Seen Bolstering Domestic Generics
Innovative ‘Quick Followers’ Grabbing China Investment
Asia Attracts Manufacturing Capital As Companies Eye Expanding Needs
Advertisement
UsernamePublicRestriction

Register

PS118439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel